Brokerages predict that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will report $20.40 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Esperion Therapeutics’ earnings, with estimates ranging from $9.00 million to $50.00 million. Esperion Therapeutics posted sales of $1.84 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 1,008.7%. The business is expected to announce its next earnings results after the market closes on Tuesday, May 4th.
On average, analysts expect that Esperion Therapeutics will report full year sales of $107.55 million for the current year, with estimates ranging from $80.00 million to $141.82 million. For the next fiscal year, analysts anticipate that the business will report sales of $226.85 million, with estimates ranging from $100.00 million to $479.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, February 22nd. The biopharmaceutical company reported ($3.89) EPS for the quarter, missing the consensus estimate of ($3.76) by ($0.13). The company had revenue of $9.64 million for the quarter, compared to analyst estimates of $12.52 million. Esperion Therapeutics had a negative return on equity of 629.88% and a negative net margin of 46.15%. The business’s revenue for the quarter was up 881.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.26) earnings per share.
Several equities analysts recently weighed in on ESPR shares. Jefferies Financial Group lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $40.00 to $30.00 in a research report on Friday, February 12th. Needham & Company LLC cut their price objective on shares of Esperion Therapeutics from $150.00 to $134.00 and set a “strong-buy” rating on the stock in a research report on Wednesday, March 3rd. Bank of America lowered shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $52.00 to $35.00 in a research report on Friday, January 15th. The Goldman Sachs Group lowered shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the company from $44.00 to $24.00 in a research report on Tuesday, February 9th. Finally, Morgan Stanley initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, March 17th. They issued an “equal weight” rating and a $30.00 price target on the stock. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics has a consensus rating of “Hold” and a consensus price target of $50.60.
ESPR traded down $1.11 during midday trading on Thursday, hitting $25.59. 796,249 shares of the company’s stock traded hands, compared to its average volume of 719,737. The company has a market cap of $720.51 million, a PE ratio of -6.40 and a beta of 1.48. The stock’s fifty day simple moving average is $27.92 and its 200-day simple moving average is $28.95. Esperion Therapeutics has a one year low of $23.90 and a one year high of $53.73.
Several institutional investors have recently added to or reduced their stakes in ESPR. Perigon Wealth Management LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter valued at about $36,000. Nisa Investment Advisors LLC raised its holdings in Esperion Therapeutics by 843.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,405 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 2,150 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Esperion Therapeutics by 75.3% during the 4th quarter. Pacer Advisors Inc. now owns 4,236 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,820 shares during the last quarter. Marshall Wace LLP bought a new stake in Esperion Therapeutics during the 1st quarter worth about $186,000. Finally, Brinker Capital Investments LLC bought a new stake in Esperion Therapeutics during the 3rd quarter worth about $220,000.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.